In addition to the genes involved in the 'HLA barrier' in solid organ and hematopoietic stem cell transplantation (HSCT), and to the polymorphisms of the KIR family genes of natural killer cell receptors, there has been growing attention in the past few years regarding the role of other gene polymorphisms of molecules potentially involved in immune reactions following HSCT. 1 In particular, attention has been paid to the sequence polymorphisms of cytokine and cytokine gene receptor genes, as these molecules are involved in the modulation of host response to tissue injury and inflammation, with the ensuing activation of donor competent cells 2 (for a recent extensive review, please refer to Petersdorf 1 ). Beyond the events linked to the T-cell receptor activation that follows the binding of T cell to HLA molecule-peptide complex, the balance between T-cell activation and inactivation is dependent on a system of antigen-independent signaling molecules, the B7(CD80/CD86)/CD28 interaction pathway. The cytotoxic T-cell CTLA-4 antigen is highly homologous with regard to CD28, and competes for B7 binding, resulting overall in downregulation of T-cell response; thus, CTLA-4 supposedly plays a key role in tolerance regulation. 3 The association of some CTLA-4 gene polymorphisms, possibly causing a reduction of mRNA and protein levels, with a variety of autoimmune disorders, has been previously reported. 4 Recently, Perez-Garcia et al. 5 reported that the clinical outcomes of recipients of HLA-identical allogeneic stem cell transplantation from a sibling donor could be predicted by the analysis of CTLA-4 polymorphism. They studied two common CTLA-4 polymorphisms in 536 HLAidentical sibling donors for allogeneic HSCT and found that the donor CT60 polymorphism reduced overall survival (hazard ratio (HR), 3.80), due to higher incidence of relapse (HR, 1.71), when at least one G allele was present, and increased the development of acute GVHD (HR, 1.54) in the presence of the AA genotype.
We wish to report our experience on CTLA-4 genotyping in the setting of HLA-identical matched unrelated donor (MUD) transplantation. We studied 147 recipients of a myeloablative MUD transplant and their donors; the recipient/donor pairs were matched for HLA A, B and C at least at the antigen level, and all were genotyped for DRB1 and DQB1 alleles. GVHD prophylaxis included methotrexate and cyclosporin A plus antithymocyte globulin. The þ 49AG (rs231775, according to the National Center for Biotechnology Information dbSNP nomenclature) and CT60 (rs3087243) polymorphisms in CTLA-4 were analyzed, employing the same methodology as Perez-Garcia et al. 5 We found no significant association of either CTLA-4 polymorphism with overall survival (HR for the GG and AG genotypes was 0.90 (95% confidence interval (CI): 0.77-2.34) as compared with HR 0.95 (95% CI 0.65-5.18) for the AA genotype). Furthermore, neither CTLA-4 polymorphisms influenced disease recurrence. On the other hand, we found that donor AA genotype at rs3087243 predicted for both grade III-IV acute and extensive chronic GVHD by multivariate analysis that included common potential influential factors (Table 1) . Finally, we found no correlation between rs231775 haplotypes and acute or chronic GVHD occurrence (not shown). These data are similar to those reported by Perez-Garcia et al.
5, in terms of the association between the rs3087243 genotype and GVHD, whereas they differ regarding the influence on survival or disease recurrence. We feel that the different transplant settings (sibling versus MUD donor), and possibly the smaller number of patients in our study, are the most obvious explanations for these discrepancies.
Response to host-damaged cells after preparative therapy and exposure to endogenous bacteria antigens might represent the triggering events in GVHD development, as a step in the activation of specific immunity pathways.
2 CD14 functions as an innate pattern recognition receptor, and after binding to lipopolysaccharide, promotes signaling through the toll-like receptor-4 . 6 A TT polymorphism at À159 in the CD14 promoter (rs2569190) has been associated with increased CD14 transcriptional activity, resulting in a higher density of CD14 on monocyte membrane and enhanced innate immune activation; 7 also, the circulating levels of soluble CD14 are increased. 8 Reduced post transplant graft survival following lung transplantation has been observed in patients with the TT genotype. 9 Thus, we sought to determine the CD14 promoter polymorphism in our patient population, employing a previously described Real-Time methodology. 10 We found that recipient TT genotype was associated with a significantly higher-risk of both acute and chronic GVHD in multivariate analysis (Table 1) , whereas donor genotype showed no correlation with GVHD occurrence. Conversely, we found no significant association between rs2569190 polymorphism (either in the donor or the recipient) and the rate of infections, overall survival or incidence of relapse (not shown).
Thus, the present data add to the growing body of information that common allelic variants in promoter regions of genes encoding for molecules involved in either the innate (CD14) or adoptive (CTLA-4) immune reactions are associated with an increased risk of GVHD after allogeneic stem cell transplantation. Prospectively, these molecules represent potential targets for novel therapeutic interventions. Acute GVHD includes only grade III-IV disease, whereas chronic GVHD, only extensive disease. CTLA-4 polymorphism refers to the donor AA genotype at CT60; CD14 polymorphism refers to the recipient TT genotype at À159. Hazard ratio (HR) and 95% confidence interval (CI) were calculated using multivariate analysis adjusted for age, donor/recipient cytomegalovirus status, BM or PBSC source and sex mismatch.
